Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 8,158 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Completed Phase 4 Interventional Results available

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

NCT02891850
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

NCT02551991
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
nal-IRI, 5 fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
29
States / cities
Mobile, Alabama • Avondale, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 30, 2026, 5:29 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of BAF312 in Dermatomyositis

NCT02029274
View directory record Official record
Conditions
Active Dermatomyositis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00255190
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
181
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 178 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

NCT00415597
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 30, 2026, 5:29 AM EDT
Recruiting Phase 1 Interventional

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07277413
View directory record Official record
Conditions
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions
IDE892, IDE397
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 5:29 AM EDT
Approved For Marketing No phase listed Expanded access

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

NCT00499720
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Interventions
Aztreonam Lysine for Inhalation
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
U.S. locations
64
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

NCT02357459
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
FX006, Placebo, TCA IR 40
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 30, 2026, 5:29 AM EDT
Active, not recruiting No phase listed Observational

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
45
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01178073
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
ambrisentan, tadalafil
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 30, 2026, 5:29 AM EDT
Recruiting Not applicable Interventional

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

NCT04634240
View directory record Official record
Conditions
Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
University of British Columbia
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
55
States / cities
Huntsville, Alabama • Phoenix, Arizona • Palo Alto, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 30, 2026, 5:29 AM EDT
Completed No phase listed Observational

Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma

NCT00900250
View directory record Official record
Conditions
Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Ann Arbor Stage III Childhood Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
1,271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 123 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma

NCT01781468
View directory record Official record
Conditions
Fatigue
Interventions
armodafinil 150 mg, Placebo, armodafinil 250 mg
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
365
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Back to ECE Safely With SAGE: Reducing COVID-19 Transmission in Hispanic and Low-income Preschoolers

NCT05178290
View directory record Official record
Conditions
COVID-19 Testing, Children, Preschool, Parents, Child Development, Self-Control, Exercise, Diet, Healthy
Interventions
CHILD back-to-ECE COVID-19 saliva testing, ECE personnel back-to-ECE COVID-19 saliva screening, SAGE garden programming
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
3 Years and older
Enrollment
1,356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 30, 2026, 5:29 AM EDT
Completed No phase listed Observational

Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung

NCT01793246
View directory record Official record
Conditions
Lung Neoplasms, Disorder Related to Lung Transplantation
Interventions
probe based laser endomicroscopy (pCLE)
Device
Lead sponsor
Mauna Kea Technologies
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

NCT02573324
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414
Drug · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
68
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

NCT04666259
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
ABL001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
Anchorage, Alaska • Phoenix, Arizona • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 30, 2026, 5:29 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

NCT02849496
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography, Questionnaire Administration, X-Ray Imaging
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

NCT01430754
View directory record Official record
Conditions
Non-24-Hour Sleep-Wake Disorder
Interventions
tasimelteon, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 4 Interventional Results available

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

NCT01970410
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
teriflunomide
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
21 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Latham, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02338960
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Bremelanotide, Placebo
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 30, 2026, 5:29 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Oct 30, 2026, 5:29 AM EDT
Active, not recruiting Phase 4 Interventional

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

NCT03417388
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
Drug · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2,476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
80
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 30, 2026, 5:29 AM EDT
Completed Not applicable Interventional

Dural Graft Equivalent Comparison Trial

NCT01667770
View directory record Official record
Conditions
Chiari Malformation
Interventions
decompression of Chiari malformation
Procedure
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 30, 2026, 5:29 AM EDT